A recent study suggests that people who stop using popular slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Published data in a major medical journal shows that while obese people can lose about a fifth of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People using these medications must be informed of the potential of quick weight regain when the medication ends," cautioned researcher Dr. Susan Jebb.
This pace of regain suggests a return to starting weight in about a year and a half.
Weighing Treatments
The research, which examined dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting generally experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts propose the mechanism of the injections explains the amplified regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
The NHS advise the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, due to the high risk of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who say that the results "highlight the persistent nature of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have come off the medication report a powerful resurgence of cravings.
"It felt as if something that goes on and I was suddenly starving," described an individual.
The struggle is compounded if patients have not adopted sustainable lifestyle or habit changes during treatment.
Growing Use
Figures indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Adoption is higher among females than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits relies on integrated behavioural support.
